Success Metrics

Clinical Success Rate
76.5%

Based on 13 completed trials

Completion Rate
76%(13/17)
Active Trials
1(4%)
Results Posted
100%(13 trials)
Terminated
4(17%)

Phase Distribution

Ph early_phase_1
1
4%
Ph not_applicable
3
13%
Ph phase_2
5
21%
Ph phase_1
8
33%
Ph phase_3
3
13%
Ph phase_4
4
17%

Phase Distribution

9

Early Stage

5

Mid Stage

7

Late Stage

Phase Distribution24 total trials
Early Phase 1First-in-human
1(4.2%)
Phase 1Safety & dosage
8(33.3%)
Phase 2Efficacy & side effects
5(20.8%)
Phase 3Large-scale testing
3(12.5%)
Phase 4Post-market surveillance
4(16.7%)
N/ANon-phased studies
3(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.9%

13 of 21 finished

Non-Completion Rate

38.1%

8 ended early

Currently Active

1

trials recruiting

Total Trials

24

all time

Status Distribution
Active(1)
Completed(13)
Terminated(8)
Other(2)

Detailed Status

Completed13
Withdrawn4
Terminated4
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
1
Success Rate
76.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.2%)
Phase 18 (33.3%)
Phase 25 (20.8%)
Phase 33 (12.5%)
Phase 44 (16.7%)
N/A3 (12.5%)

Trials by Status

withdrawn417%
terminated417%
recruiting14%
completed1354%
unknown28%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT02615184Phase 2

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Terminated
NCT02616302Phase 2

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Recruiting
NCT01216293Phase 1

Effect of Dexlansoprazole on Bone Homeostasis

Completed
NCT04877834Phase 1

Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.

Completed
NCT03202537Early Phase 1

Effectiveness of Physiologic Testing in PPI Non-Responders

Completed
NCT02442752Phase 1

Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

Withdrawn
NCT01317472Not Applicable

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

Terminated
NCT02873689Phase 3

Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients

Completed
NCT03316976Phase 1

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

Completed
NCT02873702Phase 3

Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

Terminated
NCT02351960Phase 4

Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease

Completed
NCT01328392Not Applicable

Evaluating Treatment Response in Laryngo-Pharyngeal Reflux

Withdrawn
NCT02162758Phase 2

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

Terminated
NCT01149395Phase 1

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

Completed
NCT02759393Phase 4

Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis

Unknown
NCT01093755Phase 4

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

Completed
NCT01642615Phase 2

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

Completed
NCT02096458Phase 1

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

Completed
NCT01642602Phase 2

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Completed
NCT00928161Not Applicable

Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
24